| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 219.38 | 6.9% | 26.6% |
| Total Income | 221.78 | 5.5% | 24.0% |
| Expenditure | 157.51 | 3.6% | 20.8% |
| PBT | 64.27 | 10.4% | 35.7% |
| Net Profit | 47.93 | 11.0% | 37.5% |
| OPM | 43.54% | 1.61pp | 4.38pp |
| NPM | 21.61% | 1.08pp | 2.11pp |
| EPS | 4.66 | 10.9% | 37.9% |
Vijaya Diagnostics: FY26 Revenue Crosses ₹800 Cr, Up 19.5% YoY
07 May 2026 · 7 May, 8:22 pm
Summary
Vijaya Diagnostic Centre Limited announced robust financial results for Q4 FY26 and the full fiscal year FY26. For Q4 FY26, revenue from operations grew by an impressive 26.6% year-on-year to ₹219.38 crore, while Profit after Tax surged by 37.5% to ₹47.93 crore. The company maintained strong profitability, with its EBITDA margin for the quarter improving by 379 basis points to 43.5%. For the full fiscal year, revenue increased by 19.5% to ₹814.20 crore, with PAT growing by 20.3% to ₹172.98 crore. Management highlighted FY26 as a landmark year with revenues exceeding INR 800 crore and EBITDA margins remaining ahead of their 40% guidance, attributing this success to disciplined execution and effective network expansion, with ambitious plans for further growth and technology integration in FY27.
Key Highlights
- 1
Vijaya Diagnostic Centre Limited reported a 26.6% year-on-year revenue growth in Q4 FY26, reaching ₹219.38 crore.
- 2
For the full fiscal year FY26, revenue from operations grew by 19.5% year-on-year to ₹814.20 crore, crossing the INR 800 crore mark and outperforming its long-term guidance.
- 3
Profit after Tax (PAT) for Q4 FY26 increased by 37.5% year-on-year to ₹47.93 crore, reflecting strong bottom-line growth.
- 4
FY26 PAT rose by 20.3% year-on-year, totaling ₹172.98 crore, demonstrating consistent profitability.
- 5
EBITDA margin for Q4 FY26 significantly improved by 379 basis points to 43.5%, while the FY26 EBITDA margin stood at 41.4%, an improvement of 129 basis points year-on-year.
- 6
Total tests conducted in Q4 FY26 increased by 18.5% year-on-year to 4.49 million, driven by strong momentum in both pathology and radiology segments.
- 7
The company plans to further strengthen its presence in FY27 through the addition of 4–5 hubs and 10–12 spokes, setting up a fully automated laboratory, and introducing advanced genomic testing capabilities.
Management Comments
Ms. Suprita Reddy
FY26 was a landmark year for Vijaya, as revenues crossed INR 800 Cr, translating into a 16.5% CAGR over the five years since listing, outperforming our long-term guidance of 15%. EBITDA margins also remained ahead of our 40% guidance, reflecting disciplined execution. Over the same period, our network of centres doubled. Q4 FY26 was particularly strong, with Vijaya reporting its highest-ever quarterly revenue of INR 219 Cr. Revenue grew ~26.5% YoY, supported by ~18.5% volume growth across the network. Growth was broad-based, driven by strong momentum in both pathology and radiology segments, supported by network expansion and improving brand acceptance in newer markets. Our expansion strategy continues to deliver encouraging outcomes. The Khammam and Nandyal hubs achieved break-even within two quarters, while the Ambegaon hub in Pune achieved break-even within one year of launch, reinforcing our confidence in scaling newer geographies efficiently. Technology and automation remain key strategic priorities. We are actively deploying AI-led solutions to improve diagnostic accuracy and workflow efficiency, currently across urology and dental diagnostics, while assessing opportunities to extend AI integration into additional segments. In FY27, we intend to further strengthen our presence through the addition of 4–5 hubs and 10–12 spokes. We are also setting up a fully automated laboratory with track infrastructure at Panjagutta, Hyderabad, which is expected to enhance turnaround times and operational productivity. Additionally, we plan to introduce advanced genomic testing capabilities as part of our specialised diagnostics offering.
Informational and educational content only. Not investment advice.